Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANGPTL8 antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous, Intraperitoneal
01
Overview
ANGPTL8 antisense oligonucleotide (Angptl8-ASO) is a second-generation antisense oligonucleotide (ASO) research compound designed to target and silence the mRNA of Angiopoietin-like 8 (ANGPTL8). ANGPTL8 is an insulin-regulated protein that acts as an inhibitor of lipoprotein lipase (LPL), particularly in adipose tissue. By reducing ANGPTL8 levels, the ASO disinhibits LPL activity, which promotes the uptake of circulating triglycerides into adipose tissue and reduces ectopic lipid deposition in the liver. Preclinical studies in rodent models have shown that Angptl8-ASO treatment can significantly reduce hepatic steatosis and improve systemic insulin sensitivity. Additionally, emerging research indicates that ANGPTL8 inhibition may protect against endothelial senescence and angiogenic dysfunction in type 2 diabetes by modulating the RTN4R-PI3K/AKT/FOXO3A signaling pathway, suggesting potential applications in treating diabetic vasculopathy and atherosclerosis.
- Other names
- ANGPTL8 ASOANGPTL-8 ASOANGPTL 8 ASO
02
Targets
ANGPTL8 (Developmentally regulated endothelial locus 1)
Beyond the preview
Go deeper on ANGPTL8 antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANGPTL8 antisense oligonucleotide.